These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 27770462)
1. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Bergmann J; Müller M; Baumann N; Reichert M; Heneweer C; Bolik J; Lücke K; Gruber S; Carambia A; Boretius S; Leuschner I; Becker T; Rabe B; Herkel J; Wunderlich FT; Mittrücker HW; Rose-John S; Schmidt-Arras D Hepatology; 2017 Jan; 65(1):89-103. PubMed ID: 27770462 [TBL] [Abstract][Full Text] [Related]
2. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Hong J; Wang H; Shen G; Lin D; Lin Y; Ye N; Guo Y; Li Q; Ye N; Deng C; Meng C Sci Rep; 2016 Apr; 6():24397. PubMed ID: 27080032 [TBL] [Abstract][Full Text] [Related]
3. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Malchow S; Thaiss W; Jänner N; Waetzig GH; Gewiese-Rabsch J; Garbers C; Yamamoto K; Rose-John S; Scheller J Biochim Biophys Acta; 2011 Mar; 1812(3):290-301. PubMed ID: 21130161 [TBL] [Abstract][Full Text] [Related]
4. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. Li W; Xiao J; Zhou X; Xu M; Hu C; Xu X; Lu Y; Liu C; Xue S; Nie L; Zhang H; Li Z; Zhang Y; Ji F; Hui L; Tao W; Wei B; Wang H J Clin Invest; 2015 Nov; 125(11):4239-54. PubMed ID: 26457732 [TBL] [Abstract][Full Text] [Related]
5. Activation of signal transduction pathways during hepatic oncogenesis. Chung W; Kim M; de la Monte S; Longato L; Carlson R; Slagle BL; Dong X; Wands JR Cancer Lett; 2016 Jan; 370(1):1-9. PubMed ID: 26433160 [TBL] [Abstract][Full Text] [Related]
7. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581 [TBL] [Abstract][Full Text] [Related]
8. IL-6 pathway in the liver: From physiopathology to therapy. Schmidt-Arras D; Rose-John S J Hepatol; 2016 Jun; 64(6):1403-15. PubMed ID: 26867490 [TBL] [Abstract][Full Text] [Related]
9. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression. Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504 [TBL] [Abstract][Full Text] [Related]
10. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216 [TBL] [Abstract][Full Text] [Related]
11. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Hatting M; Spannbauer M; Peng J; Al Masaoudi M; Sellge G; Nevzorova YA; Gassler N; Liedtke C; Cubero FJ; Trautwein C Cell Death Dis; 2015 Mar; 6(3):e1667. PubMed ID: 25741592 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Moran DM; Mayes N; Koniaris LG; Cahill PA; McKillop IH Liver Int; 2005 Apr; 25(2):445-57. PubMed ID: 15780071 [TBL] [Abstract][Full Text] [Related]
13. Male-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparity. Lee SA; Kim H; Won YS; Seok SH; Na Y; Shin HB; Inn KS; Kim BJ Mol Cancer; 2015 Feb; 14(1):23. PubMed ID: 25645622 [TBL] [Abstract][Full Text] [Related]
14. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281 [TBL] [Abstract][Full Text] [Related]
15. Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma. Xie Y; Sun R; Gao L; Guan J; Wang J; Bell A; Zhu J; Zhang M; Xu M; Lu P; Cai X; Ren S; Xu P; Monga SP; Ma X; Yang D; Liu Y; Lu B; Xie W Hepatol Commun; 2022 May; 6(5):1123-1139. PubMed ID: 34981658 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Jiang R; Tan Z; Deng L; Chen Y; Xia Y; Gao Y; Wang X; Sun B Hepatology; 2011 Sep; 54(3):900-9. PubMed ID: 21674558 [TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Wang Z; Yan J; Lin H; Hua F; Wang X; Liu H; Lv X; Yu J; Mi S; Wang J; Hu ZW Hepatology; 2013 May; 57(5):1869-81. PubMed ID: 23299825 [TBL] [Abstract][Full Text] [Related]
18. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Ogata H; Kobayashi T; Chinen T; Takaki H; Sanada T; Minoda Y; Koga K; Takaesu G; Maehara Y; Iida M; Yoshimura A Gastroenterology; 2006 Jul; 131(1):179-93. PubMed ID: 16831601 [TBL] [Abstract][Full Text] [Related]
19. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]